"Australian trial has moved to commercial contract negotiations." - Have been waiting for this more than the FDA news.
Very solid quarterly and very impressive growth. Mgt working hard to come up with additional funding to support the increasing demand for their SaaS & PaaS deals without dilution. Targeting smaller clients in addition to larger ones, IME striving to become the dominate player in the region.
Add to My Watchlist
What is My Watchlist?
